Bullish indicating open at $55-$60, IPO prices at $37
On Thursday, JMP Securities adjusted their financial outlook on Ironwood Pharmaceuticals (NASDAQ:IRWD), setting a new price target of $14.00, a decrease from the previous target of $23.00. Despite the reduction, the firm maintained a Market Perform rating on the company’s shares. The adjustment comes as the stock trades near $3.72, having declined over 73% in the past year according to InvestingPro data.
Ironwood Pharmaceuticals recently announced a series of strategic changes aimed at addressing challenges and enhancing profitability. The company’s update, released on Wednesday, included a 2025 guidance for its flagship product LINZESS, as well as a comprehensive corporate restructuring plan. The restructuring is designed to improve the profitability of LINZESS and to increase investment in apraglutide, Ironwood’s developmental drug. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 3.62, suggesting adequate resources to fund its strategic initiatives.
JMP Securities analyst highlighted the company’s acknowledgment of ongoing difficulties with LINZESS but emphasized the potential of apraglutide as a key asset for future value. The analyst’s revised price target is based on a risk-adjusted, discounted cash flow (DCF) analysis.
In addition to the corporate restructuring, Ironwood also shared revised timelines for the New Drug Application (NDA) submission of apraglutide. The company now expects to submit the NDA in the third quarter of 2025, a delay from the initially planned submission in the first quarter of 2025. The postponement is intended to allow the potential inclusion of long-term extension results in the product’s label, which could enhance its profile.
The business update and subsequent price target adjustment by JMP Securities reflect Ironwood’s strategic decisions as it navigates the competitive pharmaceutical landscape, with a particular focus on maximizing the potential of its product pipeline. With the company’s next earnings report scheduled for February 13, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed Research Report, which covers key metrics and growth prospects for Ironwood Pharmaceuticals.
In other recent news, Ironwood Pharmaceuticals has announced a significant shift in its business strategy, focusing on the development of apraglutide for short bowel syndrome. This strategic move is accompanied by a workforce reduction of about 50%, projected to be completed by 2025. The company expects this restructuring to result in annual operating expense savings between $55 and $60 million.
Ironwood Pharmaceuticals has also seen changes in its executive team. Sravan K. Emany, the Senior Vice President, Chief Operating Officer, and Chief Financial Officer, has stepped down from his roles. Following his departure, Thomas McCourt, the company’s Chief Executive Officer, will serve as interim principal financial officer until a new CFO is appointed.
On the financial front, despite a 19% decline in U.S. net sales due to pricing pressures, Ironwood reported a 13% year-over-year increase in prescription demand for its product LINZESS. The total revenue for the quarter was $92 million, with a GAAP net income of $4 million and an adjusted EBITDA of $26 million.
Ironwood Pharmaceuticals may indirectly benefit from a delay in the approval of Zealand Pharma (NASDAQ:ZEAL)’s treatment for short bowel syndrome, potentially strengthening Ironwood’s position in the market. These are recent developments that provide insights into Ironwood Pharmaceuticals’ strategic direction and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.